Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'CORONARY-ARTERY THROMBOSIS' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 59 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Huber, K
      Plasminogen activator inhibitor type-1 (part two): Role for failure of thrombolytic therapy. PAI-1 resistance as a potential benefit for new fibrinolytic agents

      JOURNAL OF THROMBOSIS AND THROMBOLYSIS
    2. Chi, LG; Mertz, TE; Rogers, KL; Janiczek, N; Peng, YW; Saganek, L; Bousley, RF; Juneau, PL; Uprichard, ACG; Gallagher, KP
      Antithrombotic effect of LB-30057 (CI-1028), a new synthetic thrombin inhibitor, in a rabbit model of thrombosis: Comparison with inogatran

      JOURNAL OF THROMBOSIS AND THROMBOLYSIS
    3. Oikawa, K; Kamimura, H; Watanabe, T; Miyamoto, I; Higuchi, S
      Pharmacokinetic properties of a novel tissue-type plasminogen activator pamiteplase after single intravenous administration to rats, dogs, and monkeys

      THROMBOSIS RESEARCH
    4. Friederich, PW; Keller, TT; Biemond, BJ; Peters, RJG; Hornberger, W; Buller, HR; Levi, M
      Successful attenuation of venous thrombus growth in rabbits after the administration of a novel oral thrombin inhibitor

      THROMBOSIS AND HAEMOSTASIS
    5. Yamashita, T; Kitamori, K; Hashimoto, M; Watanabe, S; Giddings, JC; Yamamoto, J
      Conjunctive effects of the 5HT(2) receptor antagonist, sarpogrelate, on thrombolysis with modified tissue plasminogen activator in different laser-induced thrombosis models

      HAEMOSTASIS
    6. Oikawa, K; Watanabe, T; Higuchi, S
      Comparison of drug disposition between wild-type and novel tissue-type plasminogen activator pamiteplase in rats

      DRUG METABOLISM AND DISPOSITION
    7. Oikawa, K; Watanabe, T; Higuchi, S
      Comparison of receptor-mediated endocytosis kinetics between wild-type t-PA and recombinant pamiteplase in isolated rat hepatocytes and liver cell plasma membranes

      XENOBIOTICA
    8. Oikawa, K; Watanabe, T; Miyamoto, I; Higuchi, S
      Determination, pharmacokinetics and protein binding of a novel tissue-typeplasminogen activator, pamiteplase in human plasma

      XENOBIOTICA
    9. Suzuki, M; Funatsu, T; Tanaka, H; Maehara, J; Saitoh, M; Usuda, S
      Bolus injection of the modified tissue-type plasminogen activator YM866 versus bolus injection plus infusion of alteplase: Comparison of thrombolyticactivities

      CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL
    10. Matsuno, H; Kozawa, O; Ueshima, S; Matsuo, O; Collen, D; Uematsu, T
      The interaction between components of the fibrinolytic system and GPIb/V/IX of platelets thrombus formation in mice

      BRITISH JOURNAL OF PHARMACOLOGY
    11. Oberhoff, M; Karsch, KR
      Synthetic direct thrombin inhibitors in unstable angina - more questions than answers

      EUROPEAN HEART JOURNAL
    12. Bernat, A; Savi, P; Lale, A; Hoffmann, P; Herbert, JM
      The antithrombotic efficacy of the GP IIb/IIIa antagonist SR121787 is potentiated by antithrombin-dependent factor Xa inhibition without an increase in the bleeding risk in the rabbit

      JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
    13. Ito, T; Matsuno, H; Kozawa, O; Niwa, M; Sakai, N; Uematsu, T
      Comparison of the antithrombotic effects and bleeding risk of fractionatedaurin tricarboxylic acid and the GPIIb IIIa antagonist GR144053 in a hamster model of stenosis

      THROMBOSIS RESEARCH
    14. Hauptmann, J; Sturzebecher, J
      Synthetic inhibitors of thrombin and factor Xa: From bench to bedside

      THROMBOSIS RESEARCH
    15. Suzuki, M; Asano, H; Tanaka, H; Usuda, S
      Development and evaluation of a new canine myocardial infarction model using a closed-chest injection of thrombogenic material

      JAPANESE CIRCULATION JOURNAL-ENGLISH EDITION
    16. Huang, JB; Rebello, SS; Rosenberg, LA; Kaneko, M; Sakurama, T; Lucchesi, BR
      Temporary and partial inhibition of platelets by SM-20302 prevents coronary artery thrombosis in a chronic canine model

      EUROPEAN JOURNAL OF PHARMACOLOGY
    17. GUNZLER WA
      SARUPLASE - BACKGROUND AND BIOCHEMISTRY

      Reviews in contemporary pharmacotherapy
    18. TANIUCHI Y; SAKAI Y; HISAMICHI N; KAYAMA M; MANO Y; SATO K; HIRAYAMA F; KOSHIO H; MATSUMOTO Y; KAWASAKI T
      BIOCHEMICAL AND PHARMACOLOGICAL CHARACTERIZATION OF YM-60828, A NEWLYSYNTHESIZED AND ORALLY-ACTIVE INHIBITOR OF HUMAN FACTOR XA

      Thrombosis and haemostasis
    19. REBELLO SS; HUANG JB; SHIN WJ; SAITO K; KANEKO M; SAITOH Y; LUCCHESI BR
      PHARMACOKINETICS AND PHARMACODYNAMICS OF SM-20302, A GPIIB IIIA RECEPTOR ANTAGONIST, IN ANESTHETIZED DOGS/

      Journal of cardiovascular pharmacology
    20. SUZUKI M; FUNATSU T; TANAKA H; USUDA S
      YM866, A NOVEL MODIFIED TISSUE-TYPE PLASMINOGEN-ACTIVATOR, AFFECTS LEFT-VENTRICULAR FUNCTION AND MYOCARDIAL INFARCT DEVELOPMENT IN DOGS WITH CORONARY-ARTERY THROMBI

      Japanese Journal of Pharmacology
    21. MOSER M; KOHLER B; SCHMITTNER M; BODE C
      RECOMBINANT PLASMINOGEN ACTIVATORS - A COMPARATIVE REVIEW OF THE CLINICAL-PHARMACOLOGY AND THERAPEUTIC USE OF ALTEPLASE AND RETEPLASE

      Biodrugs
    22. RIPKA WC
      NEW THROMBIN INHIBITORS IN CARDIOVASCULAR-DISEASE

      CURRENT OPINION IN CHEMICAL BIOLOGY
    23. SEREBRUANY VL; SCHLOSSBERG ML; EDENBAUM LR; HERZOG WR; GURBEL PA
      EFFECTS OF INTRACORONARY DILTIAZEM ON CERTAIN HEMOSTATIC PARAMETERS DURING ACUTE MYOCARDIAL-INFARCTION IN SWINE

      International journal of cardiology
    24. HANNA GP; SMALLING RW
      RETEPLASE, A NEW 3RD-GENERATION THROMBOLYTIC AGENT

      Medicamentos de actualidad
    25. REBELLO SS; BLANK HS; ROTE WE; VLASUK GP; LUCCHESI BR
      ANTITHROMBOTIC EFFICACY OF A RECOMBINANT NEMATODE ANTICOAGULANT PEPTIDE (RNAP5) IN CANINE MODELS OF THROMBOSIS AFTER SINGLE SUBCUTANEOUS ADMINISTRATION

      The Journal of pharmacology and experimental therapeutics
    26. LAWSON CA; YAN SD; YAN SF; LIAO H; ZHOU YS; SOBEL J; KISIEL W; STERN DM; PINSKY DJ
      MONOCYTES AND TISSUE FACTOR PROMOTE THROMBOSIS IN A MURINE MODEL OF OXYGEN DEPRIVATION

      The Journal of clinical investigation
    27. BODE C; GULBA D; HUBER K; RUNGE MS
      NEW APPROACHES IN PLASMINOGEN-ACTIVATOR THERAPY

      Annals of hematology
    28. GULBA DC; BODE C; RUNGE MS; HUBER K
      THROMBOLYTIC AGENTS - AN OVERVIEW

      Annals of hematology
    29. TOKUUE J; HAYASHI J; HATA Y; NAKAHARA K; IKEDA Y
      ENHANCED PLATELET AGGREGABILITY UNDER HIGH-SHEAR STRESS AFTER TREADMILL EXERCISE IN PATIENTS WITH EFFORT ANGINA

      Thrombosis and haemostasis
    30. SMITH GF; SHUMAN RT; CRAFT TJ; GIFFORD DS; KURZ KD; JONES ND; CHIRGADZE N; HERMANN RB; COFFMAN WJ; SANDUSKY GE; ROBERTS E; VANJACKSON C
      A FAMILY OF ARGINAL THROMBIN INHIBITORS RELATED TO EFEGATRAN

      Seminars in thrombosis and hemostasis
    31. SAVAGE B; SALDIVAR E; RUGGERI ZM
      INITIATION OF PLATELET-ADHESION BY ARREST ONTO FIBRINOGEN OR TRANSLOCATION ON VON-WILLEBRAND-FACTOR

      Cell
    32. SEREBRUANY VL; SCHLOSSBERG ML; EDENBAUM LR; HERZOG WR; GURBEL PA
      INTRACORONARY MAGNESIUM AND DILTIAZEM AFFECT TO A SIMILAR EXTENT CERTAIN HEMOSTATIC FACTORS DURING ACUTE MYOCARDIAL-INFARCTION IN SWINE

      Pharmacology
    33. COOK JJ; HOLAHAN MA; LYLE EA; RAMJIT DR; SITKO GR; STRANIERI MT; STUPIENSKI RF; WALLACE AA; HAND EL; GEHRET JR; KOTHSTEIN T; DRAG MD; MCCORMICK GY; PERKINS JJ; IHLE NC; DUGGAN ME; HARTMAN GD; GOULD RJ; LYNCH JJ
      NONPEPTIDE GLYCOPROTEIN IIB IIIA INHIBITORS .8. ANTIPLATELET ACTIVITYAND ORAL ANTITHROMBOTIC EFFICACY OF L-734,217/

      The Journal of pharmacology and experimental therapeutics
    34. CHEN LY; NICHOLS WW; MATTSSON C; TEGERNILSSON AC; SALDEEN TGP; MEHTA JL
      INOGATRAN, A NOVEL DIRECT LOW-MOLECULAR-WEIGHT THROMBIN INHIBITOR, GIVEN WITH, BUT NOT AFTER, TISSUE-PLASMINOGEN ACTIVATOR, IMPROVES THROMBOLYSIS

      The Journal of pharmacology and experimental therapeutics
    35. SCHAFER AI
      ANTIPLATELET THERAPY

      The American journal of medicine
    36. BODE C; NORDT TK; PETER K; SMALLING RW; RUNGE MS; KUBLER W
      PATENCY TRIALS WITH RETEPLASE (R-PA) - WHAT DO THEY TELL US

      The American journal of cardiology
    37. CALLAS DD; IQBAL O; HOPPENSTEADT D; FAREED J
      FIBRINOLYTIC COMPROMISE BY SYNTHETIC AND RECOMBINANT THROMBIN INHIBITORS - IMPLICATIONS IN THE TREATMENT OF THROMBOTIC DISORDERS

      Clinical and applied thrombosis/hemostasis
    38. KIMBALL SD
      CHALLENGES IN THE DEVELOPMENT OF ORALLY BIOAVAILABLE THROMBIN ACTIVE-SITE INHIBITORS

      Blood coagulation & fibrinolysis
    39. MELLOTT MJ; RAMJIT DR; STABILITO II; HARE TR; SENDERAK ET; LYNCH JJ; GARDELL SJ
      VAMPIRE BAT SALIVARY PLASMINOGEN-ACTIVATOR EVOKES MINIMAL BLEEDING RELATIVE TO TISSUE-TYPE PLASMINOGEN-ACTIVATOR AS ASSESSED BY A RABBIT CUTICLE BLEEDING-TIME MODEL

      Thrombosis and haemostasis
    40. YANO K; MORIMOTO H; MORITA M; TANABE T
      THROMBOLYTIC PROPERTIES OF PROUROKINASE MUTANTS WITH MUTATION IN THE EPIDERMAL GROWTH FACTOR-LIKE DOMAIN

      Fibrinolysis
    41. BODE C; KOHLER B; SMALLING RW; RUNGE MS
      RETEPLASE (R-PA) - A NOVEL RECOMBINANT PLASMINOGEN-ACTIVATOR

      Fibrinolysis
    42. LEACH IH; BLUNDELL JW; ROWLEY JM; TURNER DR
      ACUTE ISCHEMIC LESIONS IN DEATH DUE TO ISCHEMIC-HEART-DISEASE - AN AUTOPSY STUDY OF 333 CASES OF OUT-OF-HOSPITAL

      European heart journal
    43. VERSTRAETE M
      NEW DEVELOPMENTS IN ANTIPLATELET AND ANTITHROMBOTIC THERAPY

      European heart journal
    44. VERSTRAETE M; LIJNEN HR; COLLEN D
      THROMBOLYTIC AGENTS IN DEVELOPMENT

      Drugs
    45. VERSTRAETE M; ZOLDHELYI P
      NOVEL ANTITHROMBOTIC DRUGS IN DEVELOPMENT

      Drugs
    46. SPIECKER M; MEYER J
      PROUROKINASE TREATMENT OF MYOCARDIAL-INFA RCTION

      Herz
    47. RIJKEN DC; GROENEVELD E; BARRETTBERGSHOEFF MM
      IN-VITRO STABILITY OF A TISSUE-TYPE PLASMINOGEN-ACTIVATOR MUTANT, BM-06.022, IN HUMAN PLASMA

      Thrombosis and haemostasis
    48. HARA T; YOKOYAMA A; ISHIHARA H; YOKOYAMA Y; NAGAHARA T; IWAMOTO M
      DX-9065A, A NEW SYNTHETIC, POTENT ANTICOAGULANT AND SELECTIVE INHIBITOR FOR FACTOR-XA

      Thrombosis and haemostasis
    49. KAWASAKI T; KAKU S; SAKAI Y; TAKENAKA T
      THROMBOLYTIC ACTIVITY OF YM866, A NOVEL MODIFIED TISSUE-TYPE PLASMINOGEN-ACTIVATOR, IN A RABBIT MODEL OF JUGULAR-VEIN THROMBOSIS

      Drug development research
    50. SZTAJZEL J; KARPUZ H; RUTISHAUSER W
      HEROIN ABUSE AND MYOCARDIAL-INFARCTION

      International journal of cardiology
    51. KAWASAKI T; KAKU S; TAKENAKA T; YANAGI K; OHSHIMA N
      THROMBOLYTIC ACTIVITY OF YM866, A NOVEL MODIFIED TISSUE-TYPE PLASMINOGEN-ACTIVATOR, IN A PHOTOCHEMICALLY INDUCED PLATELET-RICH THROMBOSIS MODEL

      Journal of cardiovascular pharmacology
    52. DEPIN JC; VIGIE A; CHAVERNAC G; ROUSSELOT C; LARDY C
      PHARMACODYNAMICS AND ANTITHROMBOTIC EFFECTS AFTER INTRAVENOUS ADMINISTRATION OF THE NEW THROMBOXANE A(2) RECEPTOR ANTAGONIST SODIUM NYL]AMINO]METHYL]CYCLOPENTYL]METHYL]BENZENEACETATE

      Arzneimittel-Forschung
    53. WERNS SW; ROTE WE; DAVIS JH; GUEVARA T; LUCCHESI BR
      NITROGLYCERIN INHIBITS EXPERIMENTAL THROMBOSIS AND REOCCLUSION AFTER THROMBOLYSIS

      The American heart journal
    54. DEBOER A; KLUFT C; GERLOFF J; DOOIJEWAARD G; GUNZLER WA; BEIER H; VANDERMEER FJM; COHEN AF
      PHARMACOKINETICS OF SARUPLASE, A RECOMBINANT UNGLYCOSYLATED HUMAN SINGLE-CHAIN UROKINASE-TYPE PLASMINOGEN-ACTIVATOR AND ITS EFFECTS ON FIBRINOLYTIC AND HEMOSTATIC PARAMETERS IN HEALTHY MALE-SUBJECTS

      Thrombosis and haemostasis
    55. TOPOL EJ; PLOW EF
      CLINICAL-TRIALS OF PLATELET RECEPTOR INHIBITORS

      Thrombosis and haemostasis
    56. SCHAPER W
      CORONARY-ARTERY OCCLUSION AND MYOCARDIAL- INFARCTION

      Zeitschrift fur Kardiologie
    57. SMITH GF; CRAFT TJ; QUAY JF
      PHARMACODYNAMICS OF MODIFIED TISSUE-PLASMINOGEN ACTIVATOR LY210825 INTHE CONSCIOUS DOG AS EVALUATED WITH IMMUNOCAPTURE ASSAYS

      Fibrinolysis
    58. MEYER D
      VONWILLEBRAND-FACTOR - A TARGET FOR INHIBITION OF THROMBOSIS

      Nouvelle revue francaise d'hematologie
    59. RAMJIT DR; LYNCH JJ; SITKO GR; MELLOTT MJ; HOLAHAN MA; STABILITO II; STRANIERI MT; ZHANG GX; LYNCH RJ; MANNO PD; CHANG CTC; NUTT RF; BRADY SF; VEBER DF; ANDERSON PS; SHEBUSKI RJ; FRIEDMAN PA; GOULD RJ
      ANTITHROMBOTIC EFFECTS OF MK-0852, A PLATELET FIBRINOGEN RECEPTOR ANTAGONIST, IN CANINE MODELS OF THROMBOSIS

      The Journal of pharmacology and experimental therapeutics


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/01/21 alle ore 14:30:53